Pediatric Food Poisoning Treatment & Management

  • Author: Sunil K Sood, MBBS, DCh, MD; Chief Editor: Russell W Steele, MD   more...
 
Updated: Mar 13, 2012
 

Medical Care

The mainstay of medical treatment in food poisoning is fluid and electrolyte replenishment. Guidelines for the diagnosis and management of food-borne illnesses have been established by the American Medical Association, American Nurses Association-American Nurses Foundation, the Centers for Disease Control and Prevention, Center for Food Safety and Applied Nutrition, the US Food and Drug Administration (FDA), Food Safety and Inspection Service, and US Department of Agriculture.[6] Most food-borne diseases (FBDs) are not amenable to specific antidotes or antimicrobial therapy, but the few exceptions are mentioned below.

  • Short incubation
    • Chemical/mushroom: Treatment varies depending on the chemical or toxin. Consult with staff at a poison control center or an emergency manual. For most agents, the care is supportive only. Exceptions include intravenous mannitol for ciguatera toxin, antihistamines for scombroid poisoning, and atropine or physostigmine for poisoning with certain mushrooms.
    • Bacterial: No specific therapy is indicated. Institute rehydration.
  • Intermediate incubation
    • Campylobacter infections: A macrolide, especially erythromycin, and possibly azithromycin, a quinolone, or a parenteral aminoglycoside (eg, gentamicin) are indicated. However, symptoms often resolve by the time culture results are received.
    • Shigella infection: Antibiotic treatment of infection is currently problematic because of increasing rates of resistance.[7] Treatment is important to prevent transmission. Azithromycin, third-generation cephalosporins (including oral cefixime or cefpodoxime), and ciprofloxacin are choices based on laboratory susceptibility testing. Consultation with a pediatric infectious diseases specialist is highly recommended.
    • Salmonella infection: Institute rehydration. Administer parenteral extended-spectrum cephalosporin if bacteremia occurs.
    • Salmonella enteric fever: A typical regimen is a parenteral cephalosporin followed by oral amoxicillin, quinolone or cefixime based on susceptibility.
    • V cholerae, V parahaemolyticus, Vibrio vulnificus: Institute rehydration; a tetracycline can be administered to children older than 8 years.
    • Enterotoxigenic E coli (ETEC): For rapid resolution of illness, a short course of a quinolone, trimethoprim-sulfamethoxazole (TMP-SMZ), azithromycin, or rifaximin can be administered on an outpatient basis.
    • Norwalklike virus, rotavirus, or other viruses acquired via the fecal-oral route: Supportive care is indicated. Rehydration is especially important for infants with rotavirus infection.
    • Botulism: Treatment is chiefly supportive, with the notable exception of infant botulism, for which an antitoxin (BabyBIG) is available from the California Department of Health Services. Contact them at (510) 231-7600 to review the indications for such treatment. Rarely, use of a botulinum antitoxin can be considered in older children by contacting the CDC at 800-CDC-INFO.
  • Long incubation
    • Enterohemorrhagic E coli (EHEC): Most studies suggest that antibiotics are likely to increase the risk of developing hemolytic-uremic syndrome (HUS). Treatment, including treatment of HUS, is supportive.
    • Yersinia enterocolitica infection: Treatment is supportive. Parenteral aminoglycosides or third-generation cephalosporins are indicated if bacteremia is present.
  • Very long incubation
    • Giardiasis: Metronidazole is the drug of choice, but tinidazole and nitazoxanide may be better tolerated.
    • Amebiasis: Metronidazole followed by an luminal agent, usually tinidazole or paromomycin, is indicated.
    • Cryptosporidiosis: The illness is brief and self-limiting. Nitazoxanide or paromomycin are considered in severe cases.
    • Cyclosporiasis: TMP-SMZ may be an effective treatment for the immunocompromised host.
    • Listeria Infection: Intravenous ampicillin or TMP-SMZ is administered to treat systemic Listeria infection.
    • Brucellosis: A combination of doxycycline and streptomycin is the regimen of first choice.
Next

Consultations

  • Consultation with an infectious disease specialist may be beneficial in complicated or unusual cases.
  • For chemical or mushroom poisonings, consult with a poison control center for advice on specific antidotes and for help with identifying the implicated mushrooms.
  • For suspected point-source outbreaks of staphylococcal toxins or infective pathogens, call the local health department. Staff members usually have information regarding the species or strain involved and its antibiotic susceptibility.
Previous
Next

Diet

  • As with other pediatric gastroenteritides, dietary restrictions are no longer are the standard of care, and the child is allowed solid foods as desired to maintain nutritional status.
Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Sunil K Sood, MBBS, DCh, MD  Professor of Clinical Pediatrics, Department of Pediatrics, Albert Einstein College of Medicine; Chief, Pediatric Infectious Diseases, Firm Director, Pediatric Unit, Schneider Children's Hospital at North Shore, North Shore University Hospital

Sunil K Sood, MBBS, DCh, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

Rosemary Johann-Liang, MD  Medical Officer, Infectious Diseases and Pediatrics, Division of Special Pathogens and Immunological Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration

Rosemary Johann-Liang, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Larry I Lutwick, MD  Professor of Medicine, State University of New York Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus

Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Robert W Tolan Jr, MD  Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: Novartis Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD  Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

References
  1. Miller MA, Sentz J, Rabaa MA, Mintz ED. Global epidemiology of infections due to Shigella, Salmonella serotype Typhi, and enterotoxigenic Escherichia coli. Epidemiol Infect. Apr 2008;136(4):433-5. [Medline].

  2. Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Pediatrics. Jul 2008;122(1):e73-82. [Medline].

  3. Shiota M, Saitou K, Mizumoto H, Matsusaka M, Agata N, Nakayama M, et al. Rapid detoxification of cereulide in Bacillus cereus food poisoning. Pediatrics. Apr 2010;125(4):e951-5. [Medline].

  4. Notes from the field: Yersinia enterocolitica infections associated with pasteurized milk --- southwestern Pennsylvania, March-August, 2011. MMWR Morb Mortal Wkly Rep. Oct 21 2011;60(41):1428. [Medline].

  5. Noah N. Food poisoning from raw fruit and vegetables. Introduction. Epidemiol Infect. Mar 2009;137(3):305-6. [Medline].

  6. American Medical Association; American Nurses Association-American Nurses Foundation; Centers for Disease Control and Prevention; Center for Food Safety and Applied Nutrition, Food and Drug Administration; Food Safety and Inspection Service, US Department of Agriculture. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm Rep. Apr 16 2004;53:1-33. [Medline].

  7. Niyogi SK. Increasing antimicrobial resistance--an emerging problem in the treatment of shigellosis. Clin Microbiol Infect. Dec 2007;13(12):1141-3. [Medline].

  8. [Best Evidence] Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis. Feb 2009;53(2):259-72. [Medline].

  9. Batz MB, Doyle MP, Morris G, et al. Attributing illness to food. Emerg Infect Dis. Jul 2005;11(7):993-9. [Medline].

  10. Friedman CR, Hoekstra RM, Samuel M, et al. Risk factors for sporadic Campylobacter infection in the United States: A case-control study in FoodNet sites. Clin Infect Dis. Apr 15 2004;38 Suppl 3:S285-96. [Medline].

  11. Hennessy TW, Marcus R, Deneen V, et al. Survey of physician diagnostic practices for patients with acute diarrhea: clinical and public health implications. Clin Infect Dis. Apr 15 2004;38 Suppl 3:S203-11. [Medline].

  12. Herwaldt BL, Beach MJ. The return of Cyclospora in 1997: another outbreak of cyclosporiasis in North America associated with imported raspberries. Cyclospora Working Group. Ann Intern Med. Feb 2 1999;130(3):210-20. [Medline]. [Full Text].

  13. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. Oct 2005;295(6-7):405-18. [Medline].

  14. Kassenborg HD, Hedberg CW, Hoekstra M, et al. Farm visits and undercooked hamburgers as major risk factors for sporadic Escherichia coli O157:H7 infection: data from a case-control study in 5 FoodNet sites. Clin Infect Dis. Apr 15 2004;38 Suppl 3:S271-8. [Medline].

  15. Mead PS, Griffin PM. Escherichia coli O157:H7. Lancet. Oct 10 1998;352(9135):1207-12. [Medline].

  16. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med. Mar 23 1998;158(6):633-8. [Medline].

  17. Morgan MR, Fenwick GR. Natural foodborne toxicants. Lancet. Dec 15 1990;336(8729):1492-5. [Medline].

  18. Schantz PM. The dangers of eating raw fish. N Engl J Med. Apr 27 1989;320(17):1143-5. [Medline].

  19. Schlech WF 3rd. Listeria gastroenteritis--old syndrome, new pathogen. N Engl J Med. Jan 9 1997;336(2):130-2. [Medline].

  20. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. Aug 1 1998;129(3):221-8. [Medline]. [Full Text].

  21. Swaminathan B, Gerner-Smidt P. The epidemiology of human listeriosis. Microbes Infect. Aug 2007;9(10):1236-43. [Medline].

  22. Varma JK, Samuel MC, Marcus R, Hoekstra RM, Medus C, Segler S. Listeria monocytogenes infection from foods prepared in a commercial establishment: a case-control study of potential sources of sporadic illness in the United States. Clin Infect Dis. Feb 15 2007;44(4):521-8. [Medline].

  23. Voetsch AC, Van Gilder TJ, Angulo FJ, et al. FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis. Apr 15 2004;38 Suppl 3:S127-34. [Medline].

  24. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. Jun 29 2000;342(26):1930-6. [Medline].

Previous
Next
 
Escherichia coli on Gram stain. Gram-negative bacilli.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.